Literature DB >> 22743644

Imaging agents for the chemokine receptor 4 (CXCR4).

Joeri Kuil1, Tessa Buckle, Fijs W B van Leeuwen.   

Abstract

The interaction between the chemokine receptor 4 (CXCR4) and stromal cell-derived factor-1 (SDF-1, also known as CXCL12) is a natural regulatory process in the human body. However, CXCR4 over-expression is also found in diseases such as cancer, where it plays a role in, among others, the metastatic spread. For this reason it is an interesting biomarker for the field of diagnostic oncology, and therefore, it is gaining increasing interest for applications in molecular imaging. Especially "small-molecule" imaging agents based on T140, FC131 and AMD3100 have been extensively studied. SDF-1, antibodies, pepducins and bioluminescence have also been used to visualize CXCR4. In this critical review reported CXCR4 targeting imaging agents are described based on their affinity, specificity and biodistribution. The level wherein CXCR4 is up-regulated in cancer patients and its relation to the different cell lines and animal models used to evaluate the efficacy of the imaging agents is also discussed (221 references).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743644     DOI: 10.1039/c2cs35085h

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   54.564


  36 in total

1.  In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

Authors:  Wojciech G Lesniak; Teshome Aboye; Samit Chatterjee; Julio A Camarero; Sridhar Nimmagadda
Journal:  Chemistry       Date:  2017-08-03       Impact factor: 5.236

2.  Molecular imaging: the emerging role of optical imaging in nuclear medicine.

Authors:  Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11       Impact factor: 9.236

3.  Gold Nanoclusters Doped with (64)Cu for CXCR4 Positron Emission Tomography Imaging of Breast Cancer and Metastasis.

Authors:  Yongfeng Zhao; Lisa Detering; Deborah Sultan; Matthew L Cooper; Meng You; Sangho Cho; Stephanie L Meier; Hannah Luehmann; Guorong Sun; Michael Rettig; Farrokh Dehdashti; Karen L Wooley; John F DiPersio; Yongjian Liu
Journal:  ACS Nano       Date:  2016-05-18       Impact factor: 15.881

4.  A benzenesulfonamide derivative as a novel PET radioligand for CXCR4.

Authors:  Yoon Hyeun Oum; Dinesh Shetty; Younghyoun Yoon; Zhongxing Liang; Ronald J Voll; Mark M Goodman; Hyunsuk Shim
Journal:  Bioorg Med Chem       Date:  2019-11-30       Impact factor: 3.641

5.  Al[18F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression.

Authors:  Xuefeng Yan; Gang Niu; Zhe Wang; Xiangyu Yang; Dale O Kiesewetter; Orit Jacobson; Baozhong Shen; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

6.  Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents.

Authors:  Ole Tietz; Nazila Kamaly; Graham Smith; Elham Shamsaei; Kishore K Bhakoo; Nicholas J Long; Eric O Aboagye
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-07-10

Review 7.  Radiotheranostics in Cancer Diagnosis and Management.

Authors:  Hossein Jadvar; Xiaoyuan Chen; Weibo Cai; Umar Mahmood
Journal:  Radiology       Date:  2018-02       Impact factor: 11.105

Review 8.  Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Authors:  Austin R Pantel; David A Mankoff
Journal:  Cancer Lett       Date:  2016-05-16       Impact factor: 8.679

9.  Heightened CXCR4 and CXCL12 expression in NF1-associated neurofibromas.

Authors:  Beren Karaosmanoglu; Çetin Y Kocaefe; Figen Söylemezoğlu; Banu Anlar; Ali Varan; İbrahim Vargel; Sükriye Ayter
Journal:  Childs Nerv Syst       Date:  2018-02-17       Impact factor: 1.475

10.  High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.

Authors:  Qi Feng; Peng Guo; Jin Wang; Xiaoyu Zhang; Hui-Chai Yang; Jian-Gang Feng
Journal:  Exp Ther Med       Date:  2018-01-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.